scispace - formally typeset
P

Patrick A. Baeuerle

Researcher at Amgen

Publications -  314
Citations -  59914

Patrick A. Baeuerle is an academic researcher from Amgen. The author has contributed to research in topics: T cell & Antigen. The author has an hindex of 115, co-authored 305 publications receiving 57875 citations. Previous affiliations of Patrick A. Baeuerle include University of Freiburg & Ludwig Maximilian University of Munich.

Papers
More filters
Journal ArticleDOI

Function and activation of NF-kappa B in the immune system.

TL;DR: The inhibition of NF-kappa B activation by antioxidants and specific protease inhibitors may provide a pharmacological basis for interfering with these acute processes in suppressing toxic/septic shock, graft-vs-host reactions, acute inflammatory reactions, severe phase response, and radiation damage.
Journal ArticleDOI

Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1.

TL;DR: It is shown that micromolar concentrations of H2O2 can induce the expression and replication of HIV‐1 in a human T cell line and suggests that diverse agents thought to activate NF‐kappa B by distinct intracellular pathways might all act through a common mechanism involving the synthesis of ROI.
Journal ArticleDOI

NF-κB: Ten Years After

TL;DR: The manuscript and the Figures and Table are based on a manuscript originally written by Gordon C. Dickinson in 2012 and then edited by David I. Dickinson and revised by David A. Dickinson.
Journal ArticleDOI

I kappa B: a specific inhibitor of the NF-kappa B transcription factor.

TL;DR: The data show the existence of a phorbol ester-responsive regulatory protein that acts by controlling the DNA binding activity and subcellular localization of a transcription factor in cells that do not express immunoglobulin kappa light chain genes.
Journal ArticleDOI

Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells.

TL;DR: It is shown that dithiocarbamates and metal chelators can potently block the activation of nuclear factor kappa B (NF-kappa B), a transcription factor involved in human immunodeficiency virus type 1 (HIV-1) expression, signaling, and immediate early gene activation during inflammatory processes.